Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Natural Killer Group 2 Member A (NKG2A)
- Target
- NKG2A
- Molecular classification
- C-type lectin-like receptors, Receptor, Immune Checkpoint
01
Overview
NKG2A is an inhibitory checkpoint receptor expressed mainly on NK and some T cell populations. It forms a heterodimeric complex with CD94 that recognizes HLA‑E ligands. Engagement transmits potent inhibitory signals through ITIM motifs—dampening cellular cytotoxicity—which plays critical roles in regulating immunity against tumors, infections, autoimmunity, inflammation, parasite infection, transplant rejection—and represents an emerging target for immunotherapeutic intervention.
- Other names
- CD159aKLRC1
02
Mechanism of action
Blocking antibodies against NKG2A prevent its interaction with HLA-E, relieving the inhibitory signal and enhancing NK/T cell cytotoxic activity.
03
Biological functions
Immune inhibitionRegulation of NK cell activityRegulation of T cell activityImmune responseHomeostasis of cytotoxic lymphocytes
04
Disease associations
CancerAutoimmune DiseasesViral InfectionsInflammationTransplant RejectionParasite Infection
05
Safety considerations
Potential for autoimmunity due to uninhibited NK/T cell activityCytokine release syndrome
06
Interacting drugs
NKG2A blocking antibodies
1 more in the full profile.
07
Biomarkers
HLA-E expression levels on tumor cellsNKG2A expression levels on immune cells
Beyond the preview
Go deeper on Natural Killer Group 2 Member A (NKG2A).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Natural Killer Group 2 Member A (NKG2A).